1. Volume 65, Issue 5, Pages 1063-1065 (November 2016)
Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease 
Julien Vionnet, Anne-Catherine Saouli, Manuel Pascual, Fabien Stucker, Laurent Arthur Decosterd, Darius Moradpour, Haithem Chtioui 
Journal of Hepatology 
Volume 65, Issue 5, Pages (November 2016)
DOI: /j.jhep
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
GS and DCV plasma trough concentrations over 24weeks of treatment in patient 1 (○) and patient 2 (■; predialysis: regular line and post dialysis: dotted line). The grey zones indicate the usually expected steady state plasma trough concentrations range for DCV 60mg qd and for GS (SOF 400mg qd) in treatment-naive patients with chronic HCV genotype 1 infection.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions